weight-loss results
produced 12% mean body-weight reduction in the class average pivotal trial at 68 weeks — substantially more than placebo and competitive with other approved weight-loss medications. This page details the clinical evidence, eligibility criteria, and what individual results look like in practice.
How effective is ?
Mean body-weight change at 68 weeks in the class average trial. Source: FDA prescribing information.
−12%
12%
Placebo−2.5%
GLP-1 class ceiling (tirzepatide / SURMOUNT-1)−22.5%
22.5%
Vs placebo
+9.5 pts
Strong active-treatment signal